Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clotrimazole + beclomethasone is a topical combination therapy developed by Biogracea Medicare, primarily indicated for the treatment of fungal skin infections associated with inflammatory symptoms. Clotrimazole is a synthetic imidazole antifungal agent that exerts its effect by inhibiting the enzyme lanosterol 14-alpha demethylase, thereby disrupting the biosynthesis of ergosterol, a critical component of the fungal cell membrane. Beclomethasone dipropionate is a potent corticosteroid that acts as a glucocorticoid receptor agonist, providing anti-inflammatory, antipruritic, and vasoconstrictive actions to alleviate redness, swelling, and itching. This combination is particularly effective for conditions like tinea pedis, tinea cruris, and cutaneous candidiasis where secondary inflammation is present.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotrimazole + beclomethasone.